In a phase II trial of patients with metastatic castration-resistant prostate cancer (PCa), combination therapy with docetaxel and curcumin was well tolerated and effective, leading in some cases to normalisation of prostate-specific antigen (PSA) levels (14% of participants) [115]. Here, KLK3 is linked to posterior cortical atrophy.